Skip to content

Homoeopathic medicines for the treatment of warts

Usefulness of Predefined Group of Homoeopathic Medicines Selected from â??Lectures on Homoeopathic Materia Medica by Dr.J.T. Kentâ?? for the Treatment of Warts with LM Potency : A Prospective Observational Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/050321
Enrollment
38
Registered
2023-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A00-B99- Certain infectious and parasitic diseases

Interventions

Intervention1: Homoeopathic LM Potency medicines: Oral Route of administration in liquid form (water as the vehicle) in 120ml amber color bottle 1 teaspoon is added in a cup of water is to be consider

Sponsors

Bakson Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Individuals aged 6 to 24 years, of either gender. Individuals suffering from cutaneous warts for variable period of time showing the symptom similarity with those 31 predefined medicines as mentioned by Dr. J T Kent in his â??Lectures on Homoeopathic Materia Medica by Dr. J.T. Kentâ?? covering the symptom warts. Patients already undergoing treatment for warts will be recruited only after having completely stopped that therapy and with a subsequent wash-out phase of 15days.

Exclusion criteria

Exclusion criteria: Patients with ano-genital and genital warts. Individuals diagnosed with unstable psychiatric illnesses or any disease affecting quality of life (QoL). Individuals having immuno-compromised state. Pregnant women and lactating mothers. Individuals having substance abuse and/or dependence, or undergoing homeopathic treatment for any chronic disease within the last 6 months.

Design outcomes

Primary

MeasureTime frame
Changes in the quantitative overall score measured by mm scale for the size of warts, changes in the number of warts and changes in the quality of life measured by CDLQI and DLQI scales in the interventional group.Timepoint: Changes in the quantitative overall score in severity of symptoms of warts measured by mm scale at baseline and thereafter every 8 weeks upto 6 months and quality of life will be measured by CDLQI and DLQI scales at baseline and thereafter at 6 months.

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Preeti Laroia

Bakson Homoeopathic Medical College and Hospital

preeti.laroia@gmail.com9312352020

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026